05/09/2024
3:22 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/09/2024
3:09 PM | 4D Molecular Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/18/2024
7:48 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/10/2024
3:05 PM | 4D Molecular Therapeutics (Filer)
| Form DEF 14A | |
04/10/2024
3:06 PM | 4D Molecular Therapeutics (Filer)
| Form DEFA14A | |
04/10/2024
3:07 PM | 4D Molecular Therapeutics (Filer)
| Form ARS | |
04/03/2024
6:18 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
The Overlooked Retirement Asset You Probably Don’t Own (Ad) 4 out of 5 Americans believe we’re on the brink of a retirement crisis.
Luckily, in these unprecedented times, we have an unprecedented solution.
Once considered a “fringe” investment, the crypto market is now taking the world by storm. Click here to access the Crypto Retirement Blueprint now. |
03/29/2024
3:52 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/20/2024
3:40 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
5:01 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
4:15 PM | 4D Molecular Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/21/2024
4:41 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2024
7:51 PM | 4D Molecular Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SC 13G/A | |
02/14/2024
8:56 AM | 4D Molecular Therapeutics (Subject)
BIOTECHNOLOGY VALUE FUND L P (Filed by)
| Form SC 13G/A | |
02/14/2024
7:43 AM | 4D Molecular Therapeutics (Subject)
Deep Track Capital, LP (Filed by)
| Form SC 13G/A | |
02/13/2024
9:56 AM | 4D Molecular Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G/A | |
02/12/2024
8:04 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/12/2024
7:22 PM | 4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/08/2024
3:50 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/07/2024
7:32 PM | 4D Molecular Therapeutics (Issuer)
Kim Robert Young (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/07/2024
6:42 PM | 4D Molecular Therapeutics (Issuer)
Kim Robert Young (Reporting)
| Form 3/A | |
02/05/2024
4:27 PM | 4D Molecular Therapeutics (Filer)
| Form 424B5 | |
02/05/2024
3:35 PM | 4D Molecular Therapeutics (Filer)
| Form S-3ASR | |
01/25/2024
3:59 PM | 4D Molecular Therapeutics (Subject)
BlackRock Inc. (Filed by)
| Form SC 13G/A | |
01/23/2024
3:50 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/08/2024
3:15 PM | 4D Molecular Therapeutics (Subject)
VIKING GLOBAL INVESTORS LP (Filed by)
| Form SC 13G/A | |
01/08/2024
3:19 PM | 4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/05/2024
4:44 PM | 4D Molecular Therapeutics (Issuer)
HALVORSEN OLE ANDREAS (Reporting)
Ott David C. (Reporting)
Shabet Rose Sharon (Reporting)
VIKING GLOBAL INVESTORS LP (Reporting)
Viking Global Opportunities GP LLC (Reporting)
Viking Global Opportunities Illiquid Investments Sub-Master LP (Reporting)
Viking Global Opportunities Parent GP LLC (Reporting)
Viking Global Opportunities Portfolio GP LLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/05/2024
3:49 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/04/2024
4:48 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/04/2024
7:30 AM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/18/2023
4:16 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/15/2023
4:24 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/22/2023
3:20 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/09/2023
3:20 PM | 4D Molecular Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/09/2023
3:23 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/26/2023
8:33 PM | 4D Molecular Therapeutics (Issuer)
Mehra Uneek (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/12/2023
8:17 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/15/2023
11:15 PM | 4D Molecular Therapeutics (Filer)
| Form EFFECT | |
07/10/2023
8:31 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/12/2023
5:23 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
This Apple-like Innovator is Revolutionizing Healthcare (Ad) AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing.
Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry |
06/06/2023
6:23 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/25/2023
6:39 PM | 4D Molecular Therapeutics (Issuer)
Tomasello Shawn (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/25/2023
6:42 PM | 4D Molecular Therapeutics (Issuer)
MILLIGAN JOHN F (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/25/2023
6:31 PM | 4D Molecular Therapeutics (Issuer)
Kasahara Noriyuki (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/25/2023
6:32 PM | 4D Molecular Therapeutics (Issuer)
Chacko Jacob (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/25/2023
6:33 PM | 4D Molecular Therapeutics (Issuer)
GRAY SUSANNAH (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/25/2023
6:35 PM | 4D Molecular Therapeutics (Issuer)
THEUER CHARLES (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/25/2023
6:37 PM | 4D Molecular Therapeutics (Issuer)
Miller-Rich Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
